Cytokinetics, Incorporated (NASDAQ:CYTK) will be discussing 3Q20 financial results with the investment community.on 4th November 2020 at 4:30 PM eastern time.
Those interested in listening to the conference call live via the Internet can visit www.cytokinetics.com
Earnings Expectation
Cytokinetics, Incorporated is reporting third quarter earnings results on Wednesday 4th November 2020, after market close.
The consensus estimates from Thomson Reuters are loss of $ 0.34 per share from $ 4.02 million in revenue. For the full year, analysts predict revenues of $ 37.39 million, while looking forward to loss of $ 2.07 per share.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 18.00 million ~ $ 22.00 million
Click Here For More Historical Outlooks Of Cytokinetics, Incorporated
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a novel fast skeletal muscle troponin activator, which is in Phase II clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy.